Investigational Drug Information for KL1333
✉ Email this page to a colleague
What is the drug development status for KL1333?
KL1333 is an investigational drug.
There have been 4 clinical trials for KL1333.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2022.
The most common disease conditions in clinical trials are Mitochondrial Diseases, MELAS Syndrome, and Mitochondrial Myopathies. The leading clinical trial sponsors are Abliva AB, Yungjin Pharm. Co., Ltd., and NeuroVive Pharmaceutical AB.
Summary for KL1333
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2022-12-01) |
| Vendors | 30 |
Recent Clinical Trials for KL1333
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | Abliva AB | Phase 2 |
| Drug-drug Interaction Study of KL1333 in Healthy Subjects | Abliva AB | Phase 1 |
| A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease | Abliva AB | Phase 1 |
Clinical Trial Summary for KL1333
Top disease conditions for KL1333
Top clinical trial sponsors for KL1333
US Patents for KL1333
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
